Evolus Publishes US Pivotal Study Results For Evolysse Form And Evolysse Smooth In Aesthetic Surgery Journal

• Data showed that both Evolysse™ Form and Evolysse™ Smooth met the primary endpoint of non-inferiority1 and demonstrated statistical superiority1 to Restylane®-L, the control product
• The study published in Aesthetic Surgery Journal supports long-term safety and effectiveness of Cold-X™ crosslinked injectable hyaluronic acid (HA) gels for the correction of dynamic facial wrinkles and folds

Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the publication of the U.S. pivotal study results for Evolysse™ Form and Evolysse™ Smooth in the Aesthetic Surgery Journal, a leading peer-reviewed journal focusing on advances in aesthetic medicine and surgery.

The multicenter, randomized, controlled, double-blind study followed 140 patients through 12 months and evaluated the long-term safety and effectiveness of Evolysse™ Form and Evolysse™ Smooth, Cold-X™ crosslinked injectable hyaluronic acid (HA) gels, for the correction of moderate to severe dynamic facial wrinkles and folds.